An AI model significantly improved recurrence risk stratification vs. recurrence score among patients with hormone ...
MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...
REDWOOD CITY, Calif., March 25, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St. Gallen International Breast Cancer Conference in Vienna ...
- Five-year outcomes from large, prospective phase III ADAPT study confirm value of the test to help guide treatment decisions in breast cancer patients with high clinical risk, including those with ...
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK’s National Institute for Health and Care Excellence (NICE) has recommended the expanded use of ...
Researchers have developed a genomic model that could improve predictions of long-term recurrence in a common form of breast ...
CYP2D6 genotype related to tamoxifen efficacy: An analysis with exclusion of potential false CYP2D6 genotype assignment caused by loss of heterozygosity in tumor tissue. This is an ASCO Meeting ...
Based on results presented at the ongoing San Antonio Breast Cancer Symposium, the gene panel was found to predict the risk of disease recurrence in women who had undergone breast conservation surgery ...
The ICM+ AI model demonstrated superior prognostic value for breast cancer recurrence compared to Oncotype DX, especially for late distant recurrences. Integration of pathomic imaging in the ICM+ ...
- Data obtained in real-life setting from more than 800 patients with node-negative or node-positive early-stage breast cancer highlight the test's impact on clinical practice with ...
A cost-effectiveness analysis has found that Oncotype DX may not be economical to make clinical decisions on adjuvant radiation treatment in patients with DCIS. A part of precision medicine involves ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback